---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000132"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:23:28.663814+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA approves Arcutis' ZORYVE foam for seborrheic dermatitis in ages 9+

## Summary
- ZORYVE (roflumilast) topical foam 0.3% approved by FDA for seborrheic dermatitis.
- Indicated for individuals 9 years of age and older.
- Prior FDA approval exists for ZORYVE cream 0.3% for plaque psoriasis (ages 6+).
- Approval expands Arcutis' commercial product portfolio into a new dermatology indication.

## SEC filing metadata
- accession: 0001787306-23-000132
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000132/0001787306-23-000132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000132/arqt-20231215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000132
- JSON: https://secwatch.observer/filing/0001787306-23-000132.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.